SEC Filings

SEC Filings

Filing date	Description	Form	View
Feb 03, 2023	Registration of up to an additional 20% of securities for any offering registered on an S-1	S-1MEF	View HTML 0001104659-23-010773.pdf 0001104659-23-010773.rtf 0001104659-23-010773.xls
Jun 30, 2015	Registration of up to an additional 20% of securities for any offering registered on a S-3	S-3MEF	View HTML 0001193125-15-240152.pdf 0001193125-15-240152.rtf 0001193125-15-240152.xls
Apr 02, 2018	Registration of up to an additional 20% of securities for any offering registered on a S-3	S-3MEF	View HTML 0001104659-18-021599.pdf 0001104659-18-021599.rtf 0001104659-18-021599.xls
Nov 08, 2007	Registration of certain classes of securities 12(b) of the Securities Exchange Act	8-A12B	View HTML 0001193125-07-240490.pdf 0001193125-07-240490.rtf 0001193125-07-240490.xls
Dec 15, 2006	REGDEX/A	REGDEX/A	View HTML
Jul 21, 2006	REGDEX	REGDEX	View HTML
Feb 13, 2008	REGDEX	REGDEX	View HTML 9999999997-08-007009.pdf 9999999997-08-007009.rtf
May 09, 2008	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001193125-08-109402.pdf 0001193125-08-109402.rtf 0001193125-08-109402.xls
Aug 07, 2008	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001193125-08-169896.pdf 0001193125-08-169896.rtf 0001193125-08-169896.xls
Nov 07, 2008	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001193125-08-229326.pdf 0001193125-08-229326.rtf 0001193125-08-229326.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE